Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Glyphic Biotechnologies
AddedFeb 15, 2024
UpdatedJun 18, 2026
Glyphic Biotechnologies

Glyphic Biotechnologies

Glyphic: A global consulting firm providing innovative business solutions with Fortune 1000 companies using top tech platforms.

HQ
New York City, NY, US
Founded
2021
Overview
Compare
Fundraising
Employees
Website

Glyphic Biotechnologies, founded with the mission to revolutionize proteomics, focuses on advancing protein sequencing technology. The company aims to provide innovative solutions that enhance the understanding of protein structures and functions, thereby driving progress in biological research and medical diagnostics. Glyphic's core service is its cutting-edge protein sequencing technology, which targets researchers and organizations in the biotechnology and pharmaceutical industries.

Notable figures affiliated with Glyphic Biotechnologies include leading experts in proteomics and biotechnology. The company has garnered attention from prominent investors in the biotech sector, contributing to its rapid growth and development. Key achievements include significant advancements in protein sequencing accuracy and efficiency, positioning Glyphic as a leader in the field. The overall impact of Glyphic Biotechnologies lies in its potential to transform proteomics research, leading to breakthroughs in disease understanding and drug development.

Glyphic Biotechnologies - Quick Facts

When was Glyphic Biotechnologies founded?

Glyphic Biotechnologies was founded in 2021.

Where is Glyphic Biotechnologies' headquarters located?

Glyphic Biotechnologies' headquarters is located in New York City, NY, US.

When was Glyphic Biotechnologies' last funding round?

Glyphic Biotechnologies' most recent funding round was for $408.9k (USD) in September 2023.

How much has Glyphic Biotechnologies raised to-date?

As of Sep 14, 2023, Glyphic Biotechnologies has raised a total of $10.6M (USD).

How many employees does Glyphic Biotechnologies have?

Glyphic Biotechnologies has 25 employees as of Feb 4, 2024.

Glyphic Biotechnologies - Classification

Ownership
  • Private
Technology
  • Analytics
Geographic Exposure
  • Global
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Protein Sequencing
Tags
  • Biotech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7371Computer Programming Services
Show 5 more industry codes
NAICS
  • 513200Software Publishers
  • 510000Information
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 7372Prepackaged Software